Amgen Inc. (AMGN) |
269.98 0.6 (0.22%) 04-26 16:00 |
Open: | 265.72 |
High: | 271.68 |
Low: | 265.72 |
Volume: | 2,436,928 |
Market Cap: | 144,687(M) |
PE Ratio: | 21.6 |
Exchange: | NASDAQ Global Select |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 288.57 |
Resistance 1: | 277.92 |
Pivot price: | 268.53 |
Support 1: | 260.68 |
Support 2: | 216.89 |
52w High: | 329.72 |
52w Low: | 211.71 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
EPS | 12.480 |
Book Value | 11.640 |
PEG Ratio | 2.90 |
Gross Profit | 0.000 |
Profit Margin (%) | 23.83 |
Operating Margin (%) | 8.15 |
Return on Assets (ttm) | 6.3 |
Return on Equity (ttm) | 135.8 |
Thu, 25 Apr 2024
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Thu, 25 Apr 2024
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Wed, 24 Apr 2024
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Mon, 22 Apr 2024
Why Amgen (AMGN) Outpaced the Stock Market Today - Yahoo Finance
Mon, 22 Apr 2024
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Thu, 18 Apr 2024
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |